822 related articles for article (PubMed ID: 27696296)
41. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
[TBL] [Abstract][Full Text] [Related]
42. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
43. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
46. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A
Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194
[TBL] [Abstract][Full Text] [Related]
47. Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells.
Zhang H; Wu H; Guan J; Wang L; Ren X; Shi X; Liang Z; Liu T
Oncotarget; 2015 Feb; 6(5):3085-97. PubMed ID: 25609203
[TBL] [Abstract][Full Text] [Related]
48. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
49. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells.
Shrikhande SV; Kleeff J; Kayed H; Keleg S; Reiser C; Giese T; Büchler MW; Esposito I; Friess H
Anticancer Res; 2006; 26(5A):3265-73. PubMed ID: 17094439
[TBL] [Abstract][Full Text] [Related]
50. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
Liu T; Fang Y; Zhang H; Deng M; Gao B; Niu N; Yu J; Lee S; Kim J; Qin B; Xie F; Evans D; Wang L; Lou W; Lou Z
Cancer Res; 2016 Feb; 76(3):572-81. PubMed ID: 26676747
[TBL] [Abstract][Full Text] [Related]
51. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
52. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
53. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
[TBL] [Abstract][Full Text] [Related]
54. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
55. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV
Br J Cancer; 2016 Feb; 114(3):269-80. PubMed ID: 26766740
[TBL] [Abstract][Full Text] [Related]
56. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.
Carapuça EF; Gemenetzidis E; Feig C; Bapiro TE; Williams MD; Wilson AS; Delvecchio FR; Arumugam P; Grose RP; Lemoine NR; Richards FM; Kocher HM
J Pathol; 2016 Jul; 239(3):286-96. PubMed ID: 27061193
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
58. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam LR; Gore J; Craven KE; Wilson JL; Korc M
Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
[TBL] [Abstract][Full Text] [Related]
59. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
[TBL] [Abstract][Full Text] [Related]
60. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Xu P; Yao J; He J; Zhao L; Wang X; Li Z; Qian J
Oncotarget; 2016 Mar; 7(12):14831-40. PubMed ID: 26894380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
